Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

In March, short sellers collectively increased their negative bets on the broader healthcare industry, as indicated by a rise ...

Pfizer (NYSE:PFE) and GSK (NYSE ... to those aged 18-59 after the FDA cleared the messenger RNA-based vaccine in 2024 for adults aged 60 years and older in 2024. “RSV can have a significant ...

In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives.

Emerging biotech leader AKESF develops Ivonescimab & Cadonilimab; while offering growth potential with US partnerships, ...

In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best large-cap value stocks to buy as the recession hits. Goldman Sachs highlighted that equities ...

Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA splicing, a process in which a precursor form of messenger RNA (mRNA) – which is used as a template for ...

Many leading pharma and biotechs have invested in messenger RNA (mRNA) technology to develop ... Bayer, GSK, Moderna, Pfizer, and Sanofi - are all racing to develop mRNA influenza vaccines.